>
Codiak BioSciences, Inc. logo

CDAK - Codiak BioSciences, Inc. Share Price

$16.86 -0.5  -2.8%

Last Trade - 12/05/21

Sector
Healthcare
Size
Small Cap
Market Cap £270.5m
Enterprise Value £196.1m
Revenue £2.06m
Position in Universe 3837th / 6853
Bullish
Bearish
Unlock CDAK Revenue
Momentum
Relative Strength (%)
1m +10.4%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -54.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.39 2.92 9.20 4.96
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 March 2021, CodiakBioSciences Inc revenues totaled $13.2M. Net loss totaledto $10.3M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

CDAK Revenue Unlock CDAK Revenue

Net Income

CDAK Net Income Unlock CDAK Revenue

Normalised EPS

CDAK Normalised EPS Unlock CDAK Revenue

PE Ratio Range

CDAK PE Ratio Range Unlock CDAK Revenue

Dividend Yield Range

CDAK Dividend Yield Range Unlock CDAK Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
CDAK EPS Forecasts Unlock CDAK Revenue
Profile Summary

Codiak BioSciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of exosome-based therapeutics. The Company has developed its engineering and manufacturing platform, engEx Platform, to develop upon the innate properties of exosomes to design, engineer and manufacture exosome therapeutics. It utilizes the engEx Platform to generate a pipeline of engineered exosomes (engEx) exosomes, focused at treating a range of diseases, including oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease. The Company's product candidates, exoSTING and exoIL-12, are developed to address solid tumors. The Company's program, exoSTING, is an exosome therapeutic candidate engineered with its engEx Platform to carry stimulator of interferon genes (STING) agonist inside the lumen of the exosome while expressing prostaglandin F2 receptor negative regulator (PTGFRN).

Directors
Last Annual December 31st, 2020
Last Interim March 31st, 2021
Incorporated June 12, 2015
No. of Shareholders: 68
No. of Employees: 105
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 22,043,883
Free Float (0.0%)
Eligible for
ISAs
SIPPs
CDAK Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CDAK
Upcoming Events for CDAK
Friday 18th June, 2021
Codiak BioSciences, Inc. Annual Shareholders Meeting
Frequently Asked Questions for Codiak BioSciences, Inc.
What is the Codiak BioSciences, Inc. share price?

As of 12/05/21, shares in Codiak BioSciences, Inc. are trading at $16.86, giving the company a market capitalisation of £270.5m. This share price information is delayed by 15 minutes.

How has the Codiak BioSciences, Inc. share price performed this year?

Shares in Codiak BioSciences, Inc. are currently trading at $16.86 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Codiak BioSciences, Inc. price has moved by % over the past year.

What are the analyst and broker recommendations for Codiak BioSciences, Inc.?

There are no analysts currently covering Codiak BioSciences, Inc..

When will Codiak BioSciences, Inc. next release its financial results?

Codiak BioSciences, Inc. is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-03-31
What is the Codiak BioSciences, Inc. dividend yield?

Codiak BioSciences, Inc. does not currently pay a dividend.

Does Codiak BioSciences, Inc. pay a dividend?

Codiak BioSciences, Inc. does not currently pay a dividend.

When does Codiak BioSciences, Inc. next pay dividends?

Codiak BioSciences, Inc. does not currently pay a dividend.

How do I buy Codiak BioSciences, Inc. shares?

To buy shares in Codiak BioSciences, Inc. you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Codiak BioSciences, Inc.?

Shares in Codiak BioSciences, Inc. are currently trading at $16.86, giving the company a market capitalisation of £270.5m.

Where are Codiak BioSciences, Inc. shares listed? Where are Codiak BioSciences, Inc. shares listed?

Here are the trading details for Codiak BioSciences, Inc.:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: CDAK
What kind of share is Codiak BioSciences, Inc.?

Based on an overall assessment of its quality, value and momentum, Codiak BioSciences, Inc. is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Codiak BioSciences, Inc. share price forecast 2021?

Shares in Codiak BioSciences, Inc. are currently priced at $16.86. At that level they are trading at 0.111% discount to the analyst consensus target price of 0.00.

Analysts covering Codiak BioSciences, Inc. currently have a consensus Earnings Per Share (EPS) forecast of -4.133 for the next financial year.

How can I tell whether the Codiak BioSciences, Inc. share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Codiak BioSciences, Inc.. Over the past six months, the relative strength of its shares against the market has been 67.43%. At the current price of $16.86, shares in Codiak BioSciences, Inc. are trading at -0.22% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Codiak BioSciences, Inc. PE Ratio?

We were not able to find PE ratio data for Codiak BioSciences, Inc..

Who are the key directors of Codiak BioSciences, Inc.?

Codiak BioSciences, Inc.'s management team is headed by:

Steven Gillis - CHM
Douglas Williams - PRE
Linda Bain - CFO
Ariel Jasie - EXO
Jan Lotvall - EXO
Jennifer Wheler - OTH
Benny Sorensen - SVP
Who are the major shareholders of Codiak BioSciences, Inc.?

Here are the top five shareholders of Codiak BioSciences, Inc. based on the size of their shareholding:

ARCH Venture Partners Venture Capital
Percentage owned: 17.48% (3.85m shares)
Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 12.77% (2.82m shares)
Flagship Ventures Venture Capital
Percentage owned: 11.83% (2.61m shares)
University of Texas Investment Management Company Endowment Fund
Percentage owned: 3.84% (847k shares)
Board of Regents of The University of Texas System Corporation
Percentage owned: 3.84% (847k shares)
Similar to CDAK
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.